Fiche publication
Date publication
mai 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BINDA Delphine
,
Pr TOUSSIROT Eric
Tous les auteurs :
Toussirot E, Michel F, Binda D, Dumoulin G
Lien Pubmed
Résumé
The past 20years of research on leptin have provided important insights into its role in rheumatoid arthritis (RA). Leptin is one of different adipokines produced by the adipose tissue that influences the endocrine system, energy homeostasis and the immune response in several ways. Leptin is known to have predominantly pro-inflammatory effects, especially in the setting of chronic inflammation. Animal models of arthritis have illustrated well the participation of leptin in the inflammatory response within the joints. In patients with RA, numerous studies have evaluated the concentrations of leptin in the bloodstream and/or the joint cavity, showing higher levels compared to control populations. Leptin has also been found to correlate with clinical or biological measurements of disease activity of RA. Conversely, the relationship between serum leptin and joint structural damage is less evident. Leptin may also promote the development of atherosclerosis in RA and may contribute to the cardiovascular consequences of the metabolic syndrome that coexists with RA. Indeed, leptin could be a link between inflammation, metabolic risk factors and cardiovascular diseases in RA. Finally, due to abnormal body composition phenotypes with an increased prevalence of obesity in RA, the therapeutic response to traditional DMARDs and/or biological agents may be attenuated. This review discusses the multiple interplays that have been described between leptin and the clinical, radiographic and therapeutic aspects of RA.
Référence
Life Sci. 2015 May 26. pii: S0024-3205(15)00257-X
